Concepedia

Xingzhi Tan

XT

Statistics

Publications

16

Citations

1.3K

H-Index

16

Active since

1999

Affiliations

Pfizer (United States)(Current)

Pearl River Community College

State University of New York

Stony Brook University

Connecticut Sea Grant

Xingzhi Tan is an author at Pfizer (United States) specializing in medicine, pharmacology, and tumor biology.

Top concepts

Publications per year

1999–2020

16

Publications

16

Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

Frank Loganzo, Xingzhi Tan, Matthew Sung et al. · Molecular Cancer Therapeutics · 2015 · 254 citations

, , +16

Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)

Matthew Sung, Xingzhi Tan, Bingwen Lu et al. · Molecular Cancer Therapeutics · 2017 · 196 citations

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules

Malathi Hari, Frank Loganzo, Tami Annable et al. · Molecular Cancer Therapeutics · 2006 · 146 citations

, , +21

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Frank Loganzo, Carolyn Discafani, Tami Annable et al. · PubMed · 2003 · 137 citations

, , +18

Comparison of the mutagenic properties of 8-oxo-7,8-dihydro-2′-deoxyadenosine and 8-oxo-7,8-dihydro-2′-deoxyguanosine DNA lesions in mammalian cells

Xingzhi Tan, Arthur P. Grollman, Shinya Shibutani · Carcinogenesis · 1999 · 117 citations

1–5 of 16